Certified by Founder
Lodge
Umoja Biopharma
start up
United States
- Seattle, Washington
- 21/01/2025
- Series C
- $100,000,000
Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies
- Industry Biotechnology Research
- Website https://www.umoja-biopharma.com/
- LinkedIn https://www.linkedin.com/company/umoja-biopharma/
Related People
Andy ScharenbergFounder
United States -
Seattle, Washington
Physician, Scientist, Entrepreneur, passionate about the impact that CAR T-cells can have on the treatment of cancer.
Autolane | $7,400,000 | (Dec 4, 2025)
Curvestone AI | $4,000,000 | (Dec 4, 2025)
Ridley | $6,400,000 | (Dec 4, 2025)
Track Titan | $5,000,000 | (Dec 4, 2025)
Curi Bio | $10,000,000 | (Dec 4, 2025)
Supper | $11,000,000 | (Dec 4, 2025)
Gradium | $70,000,000 | (Dec 4, 2025)
Juniper Biosciences | $40,000,000 | (Dec 4, 2025)
Heven AeroTech | $100,000,000 | (Dec 4, 2025)
PineAI | $25,000,000 | (Dec 4, 2025)